- Arbutus to Participate in Jefferies Global Healthcare Conference
- Arbutus to Present Imdusiran Data at EASL Congress 2024
- Arbutus to Participate in Two Upcoming Investor Conferences
- Arbutus Reports First Quarter 2024 Financial Results and Provides Corporate Update
- Arbutus Announces Retirement of Chief Scientific Officer, Michael J. Sofia, PhD, Effective December 31, 2024
- Arbutus to Report First Quarter 2024 Financial Results and Provide Corporate Update
- Arbutus Biopharma Announces Claim Construction Ruling in its Ongoing Patent Infringement Lawsuit Against Moderna
- Arbutus Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
- Arbutus to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update
- Arbutus Announces 2024 Corporate Objectives and Provides Financial Update
More ▼
Key statistics
On Thursday, Arbutus Biopharma Corp (0SGC:LSE) closed at 3.31, -2.32% below its 52-week high of 3.39, set on May 22, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | -- |
Low | -- |
Bid | -- |
Offer | -- |
Previous close | 3.31 |
Average volume | 6.31k |
---|---|
Shares outstanding | 188.72m |
Free float | 146.66m |
P/E (TTM) | -- |
Market cap | 634.09m USD |
EPS (TTM) | -0.4393 USD |
Data delayed at least 20 minutes, as of May 30 2024 18:38 BST.
More ▼